Does ZOLBETUXIMAB Cause Malignant neoplasm progression? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Malignant neoplasm progression have been filed in association with ZOLBETUXIMAB (VYLOY). This represents 6.8% of all adverse event reports for ZOLBETUXIMAB.
7
Reports of Malignant neoplasm progression with ZOLBETUXIMAB
6.8%
of all ZOLBETUXIMAB reports
6
Deaths
4
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ZOLBETUXIMAB?
Of the 7 reports, 6 (85.7%) resulted in death, 4 (57.1%) required hospitalization, and 1 (14.3%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ZOLBETUXIMAB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does ZOLBETUXIMAB Cause?
Nausea (27)
Fatigue (19)
Vomiting (19)
Dyspnoea (16)
Diarrhoea (13)
Anaemia (12)
Abdominal pain (11)
Asthenia (11)
Decreased appetite (11)
Neutropenia (9)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ZOLBETUXIMAB Alternatives Have Lower Malignant neoplasm progression Risk?
ZOLBETUXIMAB vs ZOLBETUXIMAB-CLZB
ZOLBETUXIMAB vs ZOLEDRONIC ACID
ZOLBETUXIMAB vs ZOLMITRIPTAN
ZOLBETUXIMAB vs ZOLOFT
ZOLBETUXIMAB vs ZOLPIDEM